propranolol has been researched along with Parotid Neoplasms in 15 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Parotid Neoplasms: Tumors or cancer of the PAROTID GLAND.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report the effectiveness and safety of transcatheter arterial sclerosing embolization (TASE) for the treatment of parotid infantile hemangiomas that did not respond appreciably to propranolol." | 8.02 | Transcatheter Arterial Sclerosing Embolization for the Treatment of Giant Propranolol-Resistant Infantile Hemangiomas in the Parotid Region. ( Guo, L; Li, J; Song, D; Sun, J; Wang, L; Wu, C; Zhang, Y, 2021) |
| "Hemangioma is the most common vascular tumor in infantile period, and propranolol is the first choice, but there are still a few patients with poor curative effect." | 7.88 | [Effect of treatment of infant parotid hemangioma with no response to oral propranolol]. ( Guo, XS; Nan, J; Shen, G; Tian, Y; Wang, XL, 2018) |
| "Few specific reports have addressed propranolol as a treatment for parotid hemangioma, and its mechanism remains unclear." | 7.83 | Use of propranolol for parotid hemangioma. ( Chang, L; Chen, H; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Wang, T; Yang, X; Ying, H; Yu, W, 2016) |
| "In the last few years propranolol has revolutionized infantile hemangioma therapy." | 7.83 | Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment. ( Andrzejewska, E; Chrzanowska, B; Kobos, J; Przewratil, P; Szemraj, J; Taran, K; Wnęk, A; Wyrzykowski, D, 2016) |
| "The aim of our study was to assess the efficacy and safety of oral propranolol for the treatment of parotid infantile hemangiomas." | 7.81 | Oral propranolol for parotid infantile hemangiomas. ( Cheng, C; Li, G; Liu, ZM; Sun, HL; Wang, XK; Xi, SL; Xu, DP, 2015) |
| "A brief comment on efficacy and safety of propranolol in the treatment of parotid hemangioma is presented, with illustration of a typical case." | 7.77 | Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma. ( Zheng, JW, 2011) |
| "To evaluate the short-term results and safety of propranolol for the treatment of infantile parotid hemangioma." | 7.76 | [Treatment of infantile parotid hemangioma with propranolol]. ( Ge, CX; Li, KL; Liu, XJ; Qin, ZP; Tai, MZ, 2010) |
| "To report the effectiveness and safety of transcatheter arterial sclerosing embolization (TASE) for the treatment of parotid infantile hemangiomas that did not respond appreciably to propranolol." | 4.02 | Transcatheter Arterial Sclerosing Embolization for the Treatment of Giant Propranolol-Resistant Infantile Hemangiomas in the Parotid Region. ( Guo, L; Li, J; Song, D; Sun, J; Wang, L; Wu, C; Zhang, Y, 2021) |
| "Hemangioma is the most common vascular tumor in infantile period, and propranolol is the first choice, but there are still a few patients with poor curative effect." | 3.88 | [Effect of treatment of infant parotid hemangioma with no response to oral propranolol]. ( Guo, XS; Nan, J; Shen, G; Tian, Y; Wang, XL, 2018) |
| "Few specific reports have addressed propranolol as a treatment for parotid hemangioma, and its mechanism remains unclear." | 3.83 | Use of propranolol for parotid hemangioma. ( Chang, L; Chen, H; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Wang, T; Yang, X; Ying, H; Yu, W, 2016) |
| "In the last few years propranolol has revolutionized infantile hemangioma therapy." | 3.83 | Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment. ( Andrzejewska, E; Chrzanowska, B; Kobos, J; Przewratil, P; Szemraj, J; Taran, K; Wnęk, A; Wyrzykowski, D, 2016) |
| "The aim of our study was to assess the efficacy and safety of oral propranolol for the treatment of parotid infantile hemangiomas." | 3.81 | Oral propranolol for parotid infantile hemangiomas. ( Cheng, C; Li, G; Liu, ZM; Sun, HL; Wang, XK; Xi, SL; Xu, DP, 2015) |
| "A brief comment on efficacy and safety of propranolol in the treatment of parotid hemangioma is presented, with illustration of a typical case." | 3.77 | Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma. ( Zheng, JW, 2011) |
| "To evaluate the short-term results and safety of propranolol for the treatment of infantile parotid hemangioma." | 3.76 | [Treatment of infantile parotid hemangioma with propranolol]. ( Ge, CX; Li, KL; Liu, XJ; Qin, ZP; Tai, MZ, 2010) |
| "Consumptive hypothyroidism is a rare condition usually described in association with diffuse infantile hemangioma of the liver, over-expressing type 3 iodothyronine-deiodinase." | 2.52 | Consumptive hypothyroidism associated with parotid infantile hemangioma. ( Crivellaro, C; De Corti, F; Luzzatto, C; Zanon, GF, 2015) |
| "Consumptive hypothyroidism is a rare condition related to massive infantile hemangiomas producing an excess of the thyroid-hormone-inactivating enzyme type 3 iodothyronine deiodinase." | 1.38 | Difficult treatment of consumptive hypothyroidism in a child with massive parotid hemangioma. ( Chiumello, G; Cortinovis, F; Di Frenna, M; Gelmetti, C; Passoni, A; Persani, L; Rabbiosi, S; Vigone, MC; Weber, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Harris, J | 1 |
| Phillips, JD | 1 |
| Guo, L | 1 |
| Wu, C | 1 |
| Song, D | 1 |
| Wang, L | 1 |
| Li, J | 1 |
| Sun, J | 1 |
| Zhang, Y | 1 |
| Tian, Y | 1 |
| Guo, XS | 1 |
| Nan, J | 1 |
| Wang, XL | 1 |
| Shen, G | 1 |
| Ramdhani, D | 1 |
| Seedat, RY | 1 |
| Gu, MZ | 1 |
| Wu, JL | 1 |
| Zhao, LM | 1 |
| Ni, K | 1 |
| Chen, SM | 1 |
| Chen, JR | 1 |
| Chen, F | 1 |
| Li, XY | 1 |
| De Corti, F | 1 |
| Crivellaro, C | 1 |
| Zanon, GF | 1 |
| Luzzatto, C | 1 |
| Li, G | 1 |
| Xu, DP | 1 |
| Sun, HL | 1 |
| Cheng, C | 1 |
| Liu, ZM | 1 |
| Xi, SL | 1 |
| Wang, XK | 1 |
| Chang, L | 1 |
| Jin, Y | 1 |
| Lv, D | 1 |
| Ying, H | 1 |
| Wang, T | 1 |
| Qiu, Y | 1 |
| Ma, G | 1 |
| Chen, H | 1 |
| Yu, W | 1 |
| Yang, X | 1 |
| Lin, X | 1 |
| Przewratil, P | 1 |
| Kobos, J | 1 |
| Wnęk, A | 1 |
| Szemraj, J | 1 |
| Wyrzykowski, D | 1 |
| Chrzanowska, B | 1 |
| Andrzejewska, E | 1 |
| Taran, K | 1 |
| Eivazi, B | 1 |
| Teymoortash, A | 1 |
| Stiller, S | 1 |
| Cremer, H | 1 |
| Werner, JA | 1 |
| Liu, XJ | 1 |
| Qin, ZP | 1 |
| Tai, MZ | 1 |
| Li, KL | 1 |
| Ge, CX | 1 |
| Morais, P | 1 |
| Magina, S | 1 |
| Mateus, M | 1 |
| Trindade, E | 1 |
| Jesus, JM | 1 |
| Azevedo, F | 1 |
| Zheng, JW | 1 |
| Vigone, MC | 1 |
| Cortinovis, F | 1 |
| Rabbiosi, S | 1 |
| Di Frenna, M | 1 |
| Passoni, A | 1 |
| Persani, L | 1 |
| Chiumello, G | 1 |
| Gelmetti, C | 1 |
| Weber, G | 1 |
| Humphreys-Beher, MG | 1 |
| Zelles, T | 1 |
| Maeda, N | 1 |
| Purushotham, KR | 1 |
| Cassisi, N | 1 |
| Schneyer, CA | 1 |
1 review available for propranolol and Parotid Neoplasms
| Article | Year |
|---|---|
Consumptive hypothyroidism associated with parotid infantile hemangioma.
Topics: Administration, Oral; Hemangioma; Humans; Hypothyroidism; Infant; Male; Parotid Neoplasms; Propranol | 2015 |
14 other studies available for propranolol and Parotid Neoplasms
| Article | Year |
|---|---|
Evaluating the Clinical Outcomes of Parotid Hemangiomas in the Pediatric Patient Population.
Topics: Adrenal Cortex Hormones; Drug Administration Schedule; Female; Hemangioma; Hemangioma, Capillary; Hu | 2021 |
Transcatheter Arterial Sclerosing Embolization for the Treatment of Giant Propranolol-Resistant Infantile Hemangiomas in the Parotid Region.
Topics: Antineoplastic Agents; Bleomycin; Drug Resistance, Neoplasm; Embolization, Therapeutic; Ethiodized O | 2021 |
[Effect of treatment of infant parotid hemangioma with no response to oral propranolol].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Embolization, Therapeutic; Hemangioma; Humans; In | 2018 |
Recurrent parotid cavernous haemangioma in an adolescent, successfully treated with Propranolol.
Topics: Adolescent; Hemangioma, Cavernous; Humans; Male; Parotid Neoplasms; Propranolol; Recurrence; Vasodil | 2018 |
[Controlling therapy with propranolol for infants with parotid gland hemangiomas].
Topics: Hemangioma; Humans; Infant; Parotid Gland; Parotid Neoplasms; Propranolol | 2013 |
Oral propranolol for parotid infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Color; Female; Follow-Up Studies; Hemangioma; Hum | 2015 |
Use of propranolol for parotid hemangioma.
Topics: Administration, Oral; Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Neoplasm Recurrence | 2016 |
Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment.
Topics: Angiogenesis Inhibitors; Female; Gene Expression Profiling; Hemangioma; Humans; Immunohistochemistry | 2016 |
[Use of beta blockers--a new perspective in therapy of infantile hemangiomas of the head and neck area].
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2010 |
[Treatment of infantile parotid hemangioma with propranolol].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; In | 2010 |
Efficacy and safety of propranolol in the treatment of parotid hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Infant; Liver Neoplas | 2011 |
Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Liver Neoplasms; Neop | 2011 |
Difficult treatment of consumptive hypothyroidism in a child with massive parotid hemangioma.
Topics: Adrenal Cortex Hormones; Congenital Hypothyroidism; Female; Hemangioma; Humans; Hypothyroidism; Infa | 2012 |
Cell-surface galactosyltransferase acts as a modulator of rat and human acinar cell proliferation.
Topics: Animals; Bulimia; Cell Division; Epidermal Growth Factor; Galactosyltransferases; Humans; Hyperplasi | 1990 |